Where peptides are restricted, and why

Three layers decide whether a licensed provider can consider a peptide for you: federal compounding rules, your state, and — if you compete — anti-doping rules. This page explains each in plain language. It is general information, not legal advice.

The federal layer: what the FDA has said

Two federal decisions shape almost everything a provider can do with research peptides in the United States.

1. Compounding categories. Compounding pharmacies may only use bulk substances that are FDA-approved ingredients, on an approved list, or under evaluation in "Category 1". In 2023 the FDA moved a group of popular peptides — including BPC-157, CJC-1295, ipamorelin, AOD-9604, GHK-Cu (injectable), kisspeptin-10, MOTS-c, thymosin alpha-1 and others — to Category 2, citing safety concerns. Category 2 means compounding pharmacies should not compound them while the review stands.

2. The "research use only" boundary. Products labelled for research are not lawfully sold for human use, full stop. That label is not a loophole; it is a warning.

The state layer: why your address matters

States license providers and pharmacies, regulate telehealth, and can add their own restrictions on specific substances or on compounding. A provider licensed in Florida cannot treat you in a state where they are not licensed, and a pharmacy can only ship where it is licensed.

This is why the intake asks where you live before anything else, and why a provider will say "I can't help you where you are" rather than proceed. Vitrex does not publish a state-by-state legal table because it would be out of date within weeks; the provider checks the current position for your state at intake.

The sport layer: WADA

The World Anti-Doping Agency prohibits growth-hormone secretagogues (sermorelin, CJC-1295, ipamorelin, GHRPs, tesamorelin), BPC-157, TB-500, and non-approved substances generally. DHEA and testosterone are prohibited. If you compete in a tested sport at any level, the research status is irrelevant — the ban is decisive.

Approved medicines are different

Semaglutide, tirzepatide, liraglutide, tesamorelin, bremelanotide, testosterone and the other approved medicines on this site are prescribed under their labels in every state, subject to normal prescribing rules and, for testosterone, controlled-substance rules. Compounded copies of approved drugs are a separate, changing question — the GLP-1 shortage period is the clearest recent example.

What this means in practice

Ask a provider, not a seller, what is lawfully available where you live.
Expect "no" for Category 2 peptides from a compliant provider; a "yes" without hesitation is a warning sign.
Treat "research use only" as "not for you".
If you compete, disclose it in the intake.

General education · Not medical advice · Provider approval required